Product image of Linagliptin Zentiva (Linagliptin) supplied by GNH India

Linagliptin Zentiva

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Zentiva (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Zentiva, is a DPP-4 inhibitor presented as a tablet for oral use. It helps lower blood glucose levels in adults with type 2 diabetes mellitus.
GNH India supplies Linagliptin Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Zentiva, K.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP-4 inhibitor used to improve glycaemic control in type 2 diabetes.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose levels.
  • Type 2 diabetes mellitus (add‑on therapy): enhances glycaemic control when combined with metformin, sulfonylureas or insulin.
  • Type 2 diabetes mellitus (renal impairment): provides effective glucose control without dose adjustment in patients with reduced kidney function.

How It Works

  • Linagliptin reversibly inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), which degrades incretin hormones such as GLP‑1 and GIP. By blocking DPP‑4, linagliptin increases endogenous incretin levels, leading to glucose‑dependent enhancement of insulin secretion and suppression of glucagon release, thereby improving post‑prandial and fasting blood glucose concentrations.

Side Effects

Adverse reactions reported with linagliptin are generally mild to moderate.

Common Side Effects

  • Nasopharyngitis: mild upper‑respiratory infection symptoms.
  • Headache: transient cranial discomfort.
  • Upper respiratory tract infection: cough, sore throat.
  • Dizziness: occasional light‑headedness.
  • Gastrointestinal discomfort: nausea or abdominal pain.
  • Back pain: musculoskeletal aches.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain requiring medical attention.
  • Severe allergic reactions: rash, angioedema, or anaphylaxis.
  • Hepatic injury: elevated liver enzymes or jaundice.
  • Bullous skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Hypoglycaemia: when combined with insulin or sulfonylureas.
  • Acute kidney injury: rare reports of renal function decline.

Precautions & Warnings

Linagliptin should be used with clinical monitoring and patient education.

  • Renal impairment: no dose adjustment needed, but monitor renal function periodically.
  • Hepatic impairment: use with caution; assess liver enzymes before initiation.
  • Pregnancy: safety not established; prescribe only if potential benefit justifies the risk.
  • Breastfeeding: insufficient data; consider alternative therapy.
  • Concomitant sulfonylureas or insulin: monitor for signs of hypoglycaemia.
  • Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptin may interact with other medicines that affect glucose metabolism or drug metabolism pathways.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
  • Strong CYP3A4 inducers (e.g., rifampicin): may reduce linagliptin effectiveness.

Moderate Interactions (Monitor Closely)

  • Insulin or sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed.
  • Diuretics (e.g., thiazides): may affect blood glucose control.
  • Antihypertensive agents: monitor blood pressure as glycaemic changes can influence cardiovascular status.

Frequently Asked Questions

Linagliptin Zentiva is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus, either as a stand‑alone therapy or in combination with other antidiabetic agents such as metformin, sulfonylureas or insulin.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which normally breaks down incretin hormones. By inhibiting DPP‑4, it raises endogenous GLP‑1 and GIP levels, leading to glucose‑dependent insulin release and reduced glucagon secretion, thereby lowering blood sugar.

The dose of Linagliptin Zentiva is determined by the prescribing healthcare professional based on the patient’s clinical condition, renal and hepatic function, and any concomitant medications. The prescriber will provide the appropriate dosing regimen.

Safety of linagliptin in pregnancy and lactation has not been fully established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors but is distinguished by its predominantly non‑renal elimination, meaning dose adjustment is not required in patients with renal impairment, unlike some alternatives that need renal‑based dosing changes.

Store Linagliptin Zentiva at room temperature, below 25 °C, in the original packaging. Keep the product away from moisture, direct sunlight and heat sources to maintain its stability and potency.

Linagliptin Zentiva is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise instructed by a healthcare professional.

Serious risks include pancreatitis, severe allergic reactions such as anaphylaxis, and rare skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or difficulty breathing.

Linagliptin should be avoided in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for individuals with a history of pancreatitis or severe hepatic disease, and it is not recommended for type 1 diabetes.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT